8 bulk drugs projects commissioned under PLI scheme
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Collaboration in the industry needs to be institutionalised to drive the growth.
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
he financing was significantly oversubscribed with high demand from both existing and new investors.
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Subscribe To Our Newsletter & Stay Updated